INSM•benzinga•
Insmed Incorporated Announces It Presented 11 New Abstracts At The American Thoracic Society 2025 International Conference, Including Three Prespecified Subgroup Analyses From The Phase 3 Aspen Trial Of Brensocatib In Non-cystic Fibrosis Bronchiectasis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 21, 2025 by benzinga